AIMS: Recent retrospective trials stated that a benefit of surgery for recurrent ovarian cancer may be limited to patients in whom a complete cytoreduction (R0) could be achieved. Most of them pointed out there was no difference in survival between residual disease of 0.1-1 cm (R1) and >1 cm (R2). The aim of this study was to evaluate survival benefits from cytoreduction to R1. METHODS: Between 2002 and 2006, 123 patients with recurrent epithelial ovarian cancer undergoing secondary cytoreduction were identified from tumor registry databases. RESULTS: The median age at recurrence was 51 years (range: 28-84). Fifty-one (41.5%) patients had R0, 46 (37.4%) patients had R1, and 26 (21.1%) patients had R2 resection. The median survival of the entire cohort was 31.7 months, with an estimated 5-year survival of 31.1%. The median survival and estimated 5-year survival for patients with R1 were 31.1 months and 23.9%, and there were significant differences in survival when compared to 15.6 months and 6.4% in R2 (chi(2) = 7.45, P = 0.006), 63.2 months (mean survival) and 54.4% in complete cytoreduction (chi(2) = 8.93, P = 0.0028). CONCLUSIONS: Complete secondary cytoreduction is the strongest survival determinant in recurrent epithelial ovarian cancer, whereas patients with residual disease of 0.1-1 cm may also benefit from secondary cytoreduction. (c) 2010 Wiley-Liss, Inc.
AIMS: Recent retrospective trials stated that a benefit of surgery for recurrent ovarian cancer may be limited to patients in whom a complete cytoreduction (R0) could be achieved. Most of them pointed out there was no difference in survival between residual disease of 0.1-1 cm (R1) and >1 cm (R2). The aim of this study was to evaluate survival benefits from cytoreduction to R1. METHODS: Between 2002 and 2006, 123 patients with recurrent epithelial ovarian cancer undergoing secondary cytoreduction were identified from tumor registry databases. RESULTS: The median age at recurrence was 51 years (range: 28-84). Fifty-one (41.5%) patients had R0, 46 (37.4%) patients had R1, and 26 (21.1%) patients had R2 resection. The median survival of the entire cohort was 31.7 months, with an estimated 5-year survival of 31.1%. The median survival and estimated 5-year survival for patients with R1 were 31.1 months and 23.9%, and there were significant differences in survival when compared to 15.6 months and 6.4% in R2 (chi(2) = 7.45, P = 0.006), 63.2 months (mean survival) and 54.4% in complete cytoreduction (chi(2) = 8.93, P = 0.0028). CONCLUSIONS: Complete secondary cytoreduction is the strongest survival determinant in recurrent epithelial ovarian cancer, whereas patients with residual disease of 0.1-1 cm may also benefit from secondary cytoreduction. (c) 2010 Wiley-Liss, Inc.
Authors: Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam Journal: Mol Imaging Date: 2011-04-26 Impact factor: 4.488
Authors: P Harter; A du Bois; S Mahner; J Pfisterer; O Ortmann; C Marth; D Fink; F Hilpert; U Wagner; J Sehouli Journal: Geburtshilfe Frauenheilkd Date: 2016-02 Impact factor: 2.915
Authors: R Y Zang; P Harter; D S Chi; J Sehouli; R Jiang; C G Tropé; A Ayhan; G Cormio; Y Xing; K M Wollschlaeger; E I Braicu; C A Rabbitt; H Oksefjell; W J Tian; C Fotopoulou; J Pfisterer; A du Bois; J S Berek Journal: Br J Cancer Date: 2011-08-30 Impact factor: 7.640
Authors: Thuria Al Rawahi; Alberto D Lopes; Robert E Bristow; Andrew Bryant; Ahmed Elattar; Supratik Chattopadhyay; Khadra Galaal Journal: Cochrane Database Syst Rev Date: 2013-02-28
Authors: Farr R Nezhat; Shaghayegh M Denoble; Jennifer E Cho; Douglas N Brown; Enrique Soto; Linus Chuang; Herbert Gretz; Prakash Saharia Journal: JSLS Date: 2012 Oct-Dec Impact factor: 2.172